# Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis

> **NCT01660243** · PHASE2 · TERMINATED · sponsor: **Toray Industries, Inc** · enrollment: 45 (actual)

## Conditions studied

- Uremic Pruritus

## Interventions

- **DRUG:** Nalfurafine hydrochloride(MT-9938) 2.5μg
- **DRUG:** Nalfurafine hydrochloride(MT-9938) 5μg
- **DRUG:** Nalfurafine hydrochloride(MT-9938) 10μg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01660243
- **Lead sponsor:** Toray Industries, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** This study has been terminated because of insufficient patient recruitment.
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01660243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01660243, "Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01660243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*